INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: IVOB) on January 21, 2020, reporting events occurring on January 15, 2020. The filing addresses the execution of a new employment agreement with an existing executive officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On January 15, 2020, the Company entered into an employment agreement with Michael Campbell, Chief Operating Officer and Vice President of Business Development. Key terms include:
- Base Salary: $220,000 annually.
- Incentive Bonus: Target of up to 50% of base salary contingent on board-determined goals.
- Equity Grant (Jan 17, 2020): 1,000,000 shares of common stock and an option to purchase 4,000,000 shares.
- Option Terms: Exercise price of $0.21378 per share. 25% vested immediately; the remainder vests monthly over two years.
- Termination Provisions: Three months of base salary and benefits upon termination without "cause" or for "cause." The Company may terminate without cause on 60 days' notice.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies beyond the standard terms of the employment contract.
Investor Verification Checklist
- Verify the total dilution impact of the 5,000,000 shares/options granted to Mr. Campbell against the current outstanding share count.
- Review the specific performance goals required to trigger the 50% incentive bonus, as these are determined by the board and not detailed in this summary.
- Confirm the vesting schedule and exercise price of the stock options relative to the current market price of IVOB.
- Examine the full text of Exhibit 10.1 for detailed definitions of "cause" and other contractual nuances.